drugset / Trial / NCT03891173
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will determine the highest dose of L-DOS47 that can be given in combination with vinorelbine/cisplatin, evaluate safety and tolerability of L-DOS47 when given in combination with vinorelbine/cisplatin, and assess how effective this combination is in treating patients with lung adenocarcinoma compared to patients who are given vinorelbine/cisplatin alone.
Timeline
- Start
- 2019-02-19
- Primary completion
- 2020-05-22
- Completion
- 2020-05-22
Outcome
Outcome not reported
Stopped: “Study was halted at this time due to other budgetary priorities. Completion of reporting has been delayed first due to covid restrictions and more recently due to war in Ukraine.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | L-DOS47 | Other / unclassified | 6 ug/kg | Intravenous |
| Subject | L-DOS47 | Other / unclassified | 9 ug/kg | Intravenous |
| Subject | L-DOS47 | Other / unclassified | 12 ug/kg | Intravenous |
| Subject | Vinorelbine | Small molecule | 30 mg/m2 | Intravenous |